This small molecule drug-linker conjugate features the potent cytotoxic agent Duocarmycin TM, linked via the protease-cleavable Fmoc-Val-Cit-PAB moiety. It is designed for constructing antibody-drug conjugates (ADCs) for targeted cancer therapy research, with applications in both in vitro cytotoxicity assays and in vivo preclinical efficacy studies.